Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells

Blood

Volumn 91, Issue 11, 1998, Pages 4300-4310

  Giannì, Maurizio ^b   Koken, Marcel H M ^b   Chelbi Alix, Mounira K ^b   Benoit, Gérard ^b   Lanotte, Michel ^b   Chen, Zhu ^b   De Thé, Hugues ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; HYBRID PROTEIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0032100453     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4300     Document Type: Article

References (51)

1. Warrell R, de Thé H, Wang Z, Degos L: Acute promyelocytic leukemia. New Engl J Med 329:177, 1993
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: The second decade. (overview). Cell 83:835, 1995
3. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS: PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 14:6858, 1994
4. Koken MHM, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix M, Sobzack-Thepot J, Juhlin L, Degos L, Calvo F, de Thé H: The PML growth suppressor has an altered expression in human oncogenesis. Oncogene 10:1315, 1995
5. Liu J-H, Mu Z-M, Chang K-S: PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med 181:1965, 1995
6. Daniel M-T, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, Guillemin M, Degos L, Chomienne C, de Thé H: PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82:1858, 1993
7. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333, 1994
8. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H: The t(15;17) translocation alters a nuclear body in a RA-reversible fashion. EMBO J 13:1073, 1994
9. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML/RAR α in acute promyelocytic leukemia cells. Cell 76:345, 1994
10. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaub MP, Chambon P, Pelicci PG: Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J 11:1397, 1992
11. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM: A PML RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551, 1997
12. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARalpha under control of cathepsin G regulatory sequences. Blood 89:376, 1997
13. He L-Z, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302, 1997
14. Grignani F, Ferrucci P, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci P: The acute promyelocytic leukemia specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993
15. Tsai S, Collins S: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocytic stage. Proc Natl Acad Sci USA 90:7153, 1993
16. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P: PML/RAR homodimers: Distinct binding properties and heteromeric interactions with RXR. EMBO J 12:3171, 1993
17. Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A: Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci USA 92:7401, 1995
18. Huang M, Ye Y, Chen R, Chai J, Lu J, Zhoa L, Gu L, Wang Z: Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
19. Chomienne C, Fenaux P, Degos L: Retinoid differentiation therapy in acute promyelocytic leukemia. FASEB J 10:1025, 1996
20. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway. Cancer Res 56:2945, 1996
21. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052, 1996
22. Zhang P, Wang SY, Hu LH, Shi FD, Qiu FD, Hong RJ, Han XY, Yang HF, Song YZ, Liu YP, Zhou J, Jin ZJ: Treatment of acute promyelocytic leukaemia with intravenous arsenic trioxide. Chin J Hematol 17:58, 1996
23. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345, 1997
24. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H: Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978, 1997
25. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia. Blood 77:1080, 1991
26. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner PH, Berger R, Lanotte M: A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: Isolation, morphological, immunological and molecular features. Leukemia 6:1281, 1992
27. Ruchaud S, Duprez E, Gendron MC, Houge G, Genieser HG, Jastorff B, Doskeland SO, Lanotte M: Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci USA 91:8428, 1994
28. Andersen AS, Junker S: Simple and efficient recovery of rare living lymphoid cells from a vast majority of dead cells. Nucleic Acids Res 22:5769, 1994
29. Miller WHJ, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M, Warrell RPJ: 9-cis retinoic acid induces complete remission but does not reserve clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85:3021, 1995
30. Gianni M, Zanotta S, Terao M, Rambaldi A, Garattini E: Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: Potentiation of the induction of retinoid-dependent differentiation markers. Int J Cancer 68:75, 1996
31. Pelicano L, Lee C, Schindler C, Chelbi-Alix M: Retinoic acid enhances the expression of interferon-induced proteins: Evidence for muliple mechanisms of action. Oncogene 15:2349, 1997
32. Wesselberg S, Janssen O, Rabelitz P: Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T-cells. J Immunol 150:4338, 1993
33. Silver S, Phung LT: Bacterial heavy metal resistance: New surprises. Annu Rev Microbiol 50:753, 1996
34. Gianni M, Terao M, Zanotta S, Barbui T, Rambaldi A, Garattini E: Retinoic acid and granulocyte colony-stimulating factor synergistically induce alkaline phosphatase in acute promyelocytic leukemia cells. Blood 89:1909, 1994
35. Rogaia D, Grignani F, Grignani F, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells. Leukemia 9:1467, 1995
36. Bruel A, Benoit G, De Nay D, Brown S, Lanotte M: Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. Leukemia 9:1173, 1995
37. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, Barbui T, Rambaldi A, Garattini E: Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 3:1997
38. Liu M, Iavarone A, LP F: Transcriptional activation of the human p21 waf1/cip1 gene by retinoic acid receptor. J Biol Chem 271:31723, 1996
39. Chin YE, Kitagawa M, Su WCS, Yu ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 waf1/cyp1 mediated by STAT1. Science 272:719, 1996
40. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
41. Duprez E, Lillehaug JR, Gaub MP, Lanotte M: Differential changes of retinoid-X receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells. Oncogene 12:2443, 1996
42. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH: The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88:2826, 1996
43. Koken MHM, Reid A, Quignon F, Chelbi-Alix MK, Davies JM, Kabarowski JHS, Zhu J, Dong S, Chen S-J, Chen Z, Tan CC, Licht J, Waxman S, de Thé H, Zelent A: Leukemia-associated retinoic acid receptor α fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci USA 94:10255, 1997
44. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, Chandraratna RA, Davies PJ: Activation of retinoid X receptors induces apoptosis in HL-60 cell line. Mol Cell Biol 15:3540, 1995
45. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA: p53 independent Go/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11:493, 1995
46. Oridate N, Higushi M, Suzuki S, Shroot B, Hong WK, Lotan R: Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-napthalene carboxilic acid.(CD437). Int J Cancer 70:484, 1997
47. Bruel A, Karsenty E, Schmid M, McDonnell TJ, Lanotte M: Altered sensitivity to retinoid-induced apoptosis associated with changes in the subcellular distribution of Bcl-2. Exp Cell Res 233:281, 1997
48. Chin YE, Kitagawa M, Kiuda K, Flavell RA, Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17:5328, 1997
49. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent R, Lin D, Mercer E, Kinzler K, Vogelstein B: WAF-1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
50. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15:6269, 1996
51. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94:10907, 1997